JP2019522044A - 中枢神経系におけるリンパ管を調節するための方法及び組成物 - Google Patents

中枢神経系におけるリンパ管を調節するための方法及び組成物 Download PDF

Info

Publication number
JP2019522044A
JP2019522044A JP2019515772A JP2019515772A JP2019522044A JP 2019522044 A JP2019522044 A JP 2019522044A JP 2019515772 A JP2019515772 A JP 2019515772A JP 2019515772 A JP2019515772 A JP 2019515772A JP 2019522044 A JP2019522044 A JP 2019522044A
Authority
JP
Japan
Prior art keywords
subject
meningeal
vegfr3
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522044A5 (https=
Inventor
ジョナサン・キプニス
アントワーヌ・ルーヴォー
サンドロ・ダ・メスキータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019522044A publication Critical patent/JP2019522044A/ja
Publication of JP2019522044A5 publication Critical patent/JP2019522044A5/ja
Priority to JP2021207229A priority Critical patent/JP2022031368A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019515772A 2016-06-01 2017-05-31 中枢神経系におけるリンパ管を調節するための方法及び組成物 Pending JP2019522044A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021207229A JP2022031368A (ja) 2016-06-01 2021-12-21 中枢神経系におけるリンパ管を調節するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344164P 2016-06-01 2016-06-01
US62/344,164 2016-06-01
PCT/US2017/035285 WO2017210343A1 (en) 2016-06-01 2017-05-31 Methods and compositions for modulating lymphatic vessels in the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021207229A Division JP2022031368A (ja) 2016-06-01 2021-12-21 中枢神経系におけるリンパ管を調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2019522044A true JP2019522044A (ja) 2019-08-08
JP2019522044A5 JP2019522044A5 (https=) 2020-07-09

Family

ID=60477853

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515772A Pending JP2019522044A (ja) 2016-06-01 2017-05-31 中枢神経系におけるリンパ管を調節するための方法及び組成物
JP2021207229A Pending JP2022031368A (ja) 2016-06-01 2021-12-21 中枢神経系におけるリンパ管を調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021207229A Pending JP2022031368A (ja) 2016-06-01 2021-12-21 中枢神経系におけるリンパ管を調節するための方法及び組成物

Country Status (6)

Country Link
US (1) US11944665B2 (https=)
EP (1) EP3463575B1 (https=)
JP (2) JP2019522044A (https=)
AU (1) AU2017273629B2 (https=)
CA (1) CA3025366A1 (https=)
WO (1) WO2017210343A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210343A1 (en) 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US12352767B2 (en) 2018-07-16 2025-07-08 University Of Virginia Patent Foundation Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity
CN113226283A (zh) * 2018-10-04 2021-08-06 罗切斯特大学 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送
WO2020102627A1 (en) 2018-11-16 2020-05-22 Yale University Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114949182B (zh) * 2022-04-07 2025-07-01 上海大学 一种淋巴管生成诱导剂的用途
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage
JP2026510233A (ja) * 2023-02-16 2026-04-02 ユニバーシティー オブ ロチェスター グリンパ－リンパ流出の改善

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021214A1 (en) * 1999-09-21 2001-03-29 Medgene Bioscience, Inc. Gene therapy for cerebrovascular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20080057028A1 (en) 2002-10-02 2008-03-06 Institute Nationale De La Sante Et De La Recherche Medicale (Inserm) Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells
US9415090B2 (en) * 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
US8852936B2 (en) * 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
WO2017210343A1 (en) 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
WO2020102627A1 (en) 2018-11-16 2020-05-22 Yale University Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021214A1 (en) * 1999-09-21 2001-03-29 Medgene Bioscience, Inc. Gene therapy for cerebrovascular disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CEREBROSPINAL FLUID RESEARCH, vol. Vol. 6, Suppl. 1. S4, JPN6021023297, 2009, pages 1 - 2, ISSN: 0004720138 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 461, no. 12, JPN6021023295, 2014, pages 192 - 202, ISSN: 0004720137 *
NATURE, vol. 523, JPN6021023294, 2015, pages 337 - 341, ISSN: 0004720136 *

Also Published As

Publication number Publication date
US11944665B2 (en) 2024-04-02
EP3463575A1 (en) 2019-04-10
EP3463575B1 (en) 2025-03-26
US20190269758A1 (en) 2019-09-05
CA3025366A1 (en) 2017-12-07
AU2017273629B2 (en) 2023-06-08
AU2017273629A1 (en) 2018-12-13
JP2022031368A (ja) 2022-02-18
WO2017210343A1 (en) 2017-12-07
EP3463575A4 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
JP2019522044A (ja) 中枢神経系におけるリンパ管を調節するための方法及び組成物
Simon et al. Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice
Alvarez-Vergara et al. Non-productive angiogenesis disassembles Aß plaque-associated blood vessels
US20200345812A1 (en) Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
KR101679438B1 (ko) 알츠하이머병의 검출을 위한 광학적 방법
Petratos et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation
JP2019501210A (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
Ma et al. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus
Tamura et al. The F (ab′) 2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain
US20240050529A1 (en) Modulating lymphatic vessels in neurological disease
Feng et al. Meningeal lymphatics as a therapeutic target for neurodegenerative disorders
Li et al. Rhythmic deep-brain magnetic stimulation promotes angiogenesis and inhibits apoptosis by regulating the JAK2/STAT3 pathway in rats with superior sagittal sinus thrombosis
F Wu et al. Optic neuritis: a model for the immuno-pathogenesis of central nervous system inflammatory demyelinating diseases
Hiratsuka et al. Remyelination in the medulla oblongata of adult mouse brain during experimental autoimmune encephalomyelitis
Hélie-Legoupil et al. In vivo imaging of the barrier properties of the glia limitans during health and neuroinflammation
JP2021517561A (ja) 神経学的障害及び他の障害を治療するための組成物及び方法
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
Gu et al. Pregnane X receptor activation regulate amyloid transport to improve cognition functions in Alzhermer’s disease
Casanova et al. Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinson’s disease degeneration
Wang et al. The liver and muscle secreted Hfe2-protein maintains blood brain barrier integrity
Sciacca Blood-Spinal cord-barrier breakdown and prion-like behaviour of mutant huntingtin: shedding light onto new pathological characteristics of Huntington's disease
Chen et al. NeuroD1 gene therapy converts reactive astrocytes to functional new neurons in a mouse model of Alzheimer’s disease
Wang et al. Running exercise mitigates amyloidosis in 5xFAD mice by improving the structure and function of the meningeal lymphatic system
Furtado et al. Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression
Cooper The Formation and Properties of the Fibrotic Scar After Spinal Cord Injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220307